Research programme: inflammatory bowel disease therapeutics - Tillotts PharmaAlternative Names: 5-ASA-based technology; Mesalamine-based technology
Latest Information Update: 16 Jul 2016
At a glance
- Originator PLx Pharma
- Developer Tillotts Pharma
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammatory-bowel-disease in Switzerland
- 05 Jul 2011 Early research in Inflammatory bowel disease in Switzerland (unspecified route)